Posted by Michael Wonder on 01 Nov 2023
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
1 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of epcoritamab in the NHS in England.
For the time being, epcoritamab is not recommended for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments.
